Search
vTv Therapeutics Inc
VTVTAdd to Watchlist
38.430USD
+6.765+21.36%
Close 05/14, 16:00（ET）Quotes delayed by 15 min
124.73MMarket Cap
LossP/E TTM
More Details of vTv Therapeutics Inc Company
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
vTv Therapeutics Inc Info
Ticker SymbolVTVT
Company namevTv Therapeutics Inc
IPO dateJul 30, 2015
CEOSekhri (Paul Jai)
Number of employees23
Security typeOrdinary Share
Fiscal year-endJul 30
Address3980 Premier Dr
CityHIGH POINT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27265
Phone13368410300
Websitehttps://vtvtherapeutics.com/
Ticker SymbolVTVT
IPO dateJul 30, 2015
CEOSekhri (Paul Jai)
Company Executives of vTv Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Mr. Daniel (Dan) Spiegelman
Mr. Daniel (Dan) Spiegelman
Director
Director
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
5.23K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
5.01K
+57.13%
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.82K
+61.94%
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MacAndrews & Forbes Holdings, Inc.
37.83%
Samsara BioCapital, LLC
7.58%
Fidelity Management & Research Company LLC
6.83%
Trails Edge Capital Partners LP
5.86%
Millennium Management LLC
5.71%
Other
36.18%
Shareholders
Shareholders
Proportion
MacAndrews & Forbes Holdings, Inc.
37.83%
Samsara BioCapital, LLC
7.58%
Fidelity Management & Research Company LLC
6.83%
Trails Edge Capital Partners LP
5.86%
Millennium Management LLC
5.71%
Other
36.18%
Shareholder Types
Shareholders
Proportion
Holding Company
37.83%
Investment Advisor
20.61%
Hedge Fund
9.98%
Venture Capital
7.58%
Individual Investor
1.15%
Investment Advisor/Hedge Fund
1.13%
Family Office
0.16%
Research Firm
0.15%
Other
21.41%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
47
1.41M
35.82%
+186.91K
2025Q4
44
1.18M
30.04%
+255.03K
2025Q3
47
1.15M
29.13%
+562.26K
2025Q2
54
1.51M
57.66%
-17.51K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MacAndrews & Forbes Holdings, Inc.
912.98K
23.18%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
298.50K
7.58%
-75.97K
-20.29%
Dec 31, 2025
Fidelity Management & Research Company LLC
268.86K
6.83%
+75.97K
+39.38%
Dec 31, 2025
Trails Edge Capital Partners LP
231.00K
5.86%
--
--
Dec 31, 2025
Invus Public Equities Advisors, LLC
163.00K
4.14%
--
--
Dec 31, 2025
Baker Bros. Advisors LP
148.31K
3.77%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
28.19K
0.72%
+12.90K
+84.30%
Dec 31, 2025
683 Capital Management LLC
18.27K
0.46%
+18.27K
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Date
Ex-dividend Date
Type
Ratio
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
Nov 15, 2023
Merger
40→1
